Amgen may be way late to the obesity game, but the market scouts are loving the blockbuster potential of AMG 133

Bioregnum Opinion Column by John Carroll

Amgen has been dangling another snapshot of early-stage data from its obesity drug AMG 133. And the analysts have been grabbing it and begging for more. Cowen’s Yaron Werber reminds us in a note that Amgen got the process...

Click to view original post